Loading...
•
Mar 31
Maravai Q1 2025 Earnings Report
Reported financial results for the first quarter ended March 31, 2025.
Key Takeaways
Maravai LifeSciences reported first-quarter 2025 revenue of $46.9 million, exceeding guidance. However, the company experienced a net loss of $(52.9) million and negative Adjusted EBITDA of $(10.5) million, primarily due to a lack of high-volume CleanCap orders and lower research product demand in Nucleic Acid Production, as well as a goodwill impairment charge.
First quarter 2025 revenue was $46.9 million, a 27.0% decrease year-over-year.
Nucleic Acid Production revenue decreased by 37.5% year-over-year to $28.8 million.
Biologics Safety Testing revenue was relatively flat year-over-year at $18.1 million.
Reported a net loss of $(52.9) million and Adjusted EBITDA of $(10.5) million for the quarter.
Maravai
Maravai
Maravai Revenue by Segment
Revenue by Segment
Nucleic Acid Production Revenue
CapyFin.comBiologics Safety Testing Revenue
CapyFin.com Forward Guidance
Maravai's revenue guidance for the full year 2025 remains unchanged in the range of $185.0 million to $205.0 million. This guidance is based on expectations for the existing base business and excludes potential high-volume CleanCap orders for commercial vaccine programs or potential new acquisitions.
Positive Outlook
- First quarter revenue exceeded guidance range.
- Base business revenue grew compared to the fourth quarter of 2024.
- Commitment to return-to-growth strategy.
- Customer focus, differentiated technologies, and GMP services support clients from discovery through commercialization.
- Positioned to navigate the evolving landscape and drive long-term value.
Challenges Ahead
- Revenue guidance for the full year 2025 does not include revenue from high-volume CleanCap orders for commercial phase vaccine programs.
- Guidance does not include potential new acquisitions.
- Guidance is subject to a number of risks and uncertainties.
- Dynamic and shifting macroeconomic environment.
- Reliance on a limited number of customers for a high percentage of revenue.